A prescription weight loss pill once promoted as a long-term tool for controlling appetite disappeared from the U.S. market after a major safety trial raised an uncomfortable question: Could the medicine be associated with cancer?
In February 2020, the U.S. Food and Drug Administration requested that the manufacturer of Belviq and Belviq XR voluntarily withdraw the products. The active ingredient, lorcaserin, had been prescribed to certain adults with obesity or overweight. However, an analysis of long-term clinical trial data found more cancer diagnoses among people taking lorcaserin than among those receiving a placebo.
The difference was not enormous, and the study did not prove that Belviq directly caused cancer. Nevertheless, the FDA concluded that the drug’s potential benefits no longer outweighed its possible risks. That decision turned Belviq from a relatively familiar weight management medication into a case study in why drug safety monitoring continues long after a prescription reaches pharmacy shelves.
What Was Belviq?
Belviq was the brand name for lorcaserin, a prescription medication approved by the FDA in 2012 for chronic weight management. Belviq XR, an extended-release version designed for once-daily dosing, became available later.
The medication was intended for adults with a body mass index, or BMI, of at least 30. It could also be prescribed to adults with a BMI of at least 27 who had a weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or cardiovascular disease.
How lorcaserin worked
Lorcaserin acted on serotonin 5-HT2C receptors in the brain. Activating these receptors was believed to stimulate pathways involved in fullness and appetite regulation. In less laboratory-flavored language, the medicine was supposed to help a person feel satisfied after eating less.
It was not approved as a magic pill that allowed patients to live exclusively on cheeseburgers while their bathroom scales politely looked away. Belviq was prescribed alongside a reduced-calorie eating plan and increased physical activity.
The standard immediate-release dosage was 10 milligrams twice daily. The extended-release version provided 20 milligrams once daily. Patients were generally evaluated after about 12 weeks, and treatment could be discontinued if they had not lost at least 5% of their starting weight.
How effective was Belviq for weight loss?
Earlier clinical trials found that lorcaserin produced greater average weight loss than lifestyle treatment plus placebo. In pooled studies of people without diabetes, approximately 47% of participants taking lorcaserin lost at least 5% of their initial body weight after one year, compared with roughly 23% of those receiving placebo.
The difference was meaningful for some patients, but the average effect was modest. FDA reviewers calculated that lorcaserin produced approximately seven pounds more weight loss than placebo in participants without diabetes. Individual outcomes varied considerably: some people responded well, while others saw little benefit.
Why Was Belviq Taken Off the Market?
The Belviq withdrawal was triggered by findings from a large clinical trial called CAMELLIA–TIMI 61. The FDA required the manufacturer to conduct this postmarketing study when lorcaserin was approved.
The original purpose of the trial was to determine whether the medication increased cardiovascular problems such as heart attack or stroke. This was an important question because the history of weight loss drugs contains more plot twists than a daytime soap opera. Previous appetite suppressants had been withdrawn after serious cardiovascular risks emerged.
CAMELLIA–TIMI 61 enrolled approximately 12,000 adults who were overweight or obese and had cardiovascular disease or significant cardiovascular risk factors. Participants were randomly assigned to receive either lorcaserin or a placebo, in addition to lifestyle counseling.
The cardiovascular findings were initially reassuring
The published cardiovascular results did not show a meaningful increase in major cardiovascular events among participants taking lorcaserin. The drug also helped some participants achieve sustained weight loss and improvements in certain metabolic measurements.
If the safety story had ended there, Belviq might have remained available. But long-term studies often contain secondary data that become important after researchers look beyond the primary endpoint.
The cancer imbalance changed the calculation
During the trial, 462 participants taking lorcaserin, or 7.7%, were diagnosed with cancer. In the placebo group, 423 participants, or 7.1%, received a cancer diagnosis.
That represents an absolute difference of 0.6 percentage points, or approximately six additional people diagnosed with cancer per 1,000 participants. The FDA also described the imbalance as roughly one additional cancer for every 470 patients treated with lorcaserin for one year.
Several cancer types occurred more often in the lorcaserin group, including pancreatic, colorectal, and lung cancers. There was no clear difference during the first months of treatment, but the imbalance became more noticeable with longer exposure.
In January 2020, the FDA announced that it was reviewing a possible cancer signal. On February 13, 2020, after completing its analysis, the agency requested that Eisai voluntarily remove Belviq and Belviq XR from the U.S. market. The manufacturer agreed.
Did Belviq Definitely Cause Cancer?
No direct cause-and-effect relationship was conclusively established. A higher number of cancers in one study group is a safety signal, but it does not automatically prove that the drug produced those cancers.
Participants may differ in ways that influence their baseline risk, even in a randomized trial. Cancer also develops through a complicated combination of age, genetics, environmental exposures, health conditions, lifestyle factors, and plain biological bad luck.
The CAMELLIA–TIMI 61 trial was primarily designed to study cardiovascular outcomes, not cancer. A later meta-analysis of several lorcaserin trials found a numerical increase in cancer diagnoses, but its confidence interval included the possibility of no meaningful increase. The overall result was heavily influenced by the large CAMELLIA trial.
Even with that uncertainty, regulators do not always wait for courtroom-level proof before acting. Prescription drugs must offer benefits that justify their risks. Because Belviq generally produced moderate weight loss and the cancer signal appeared to increase with longer treatment, the FDA determined that no identifiable group of patients had a sufficiently favorable benefit-risk balance.
Relative risk and absolute risk are different
News about a “cancer risk” can sound as though every former patient is standing beneath a flashing emergency siren. The numbers provide essential context.
About 92 out of every 100 participants in both trial groups were not diagnosed with cancer during the study. The difference between the groups was small in absolute terms. Still, a small increase becomes important when a medication may be used by large numbers of people for months or years, especially when other treatment choices are available.
What Should Former Belviq Users Do?
The FDA advised patients taking lorcaserin to stop using it and speak with a health care professional about alternative weight management treatments. Belviq should not be restarted, shared, purchased online, or used from an old bottle hiding in the back of a cabinet.
Do former users need special cancer screening?
The FDA did not recommend special cancer tests solely because a person previously took Belviq. Former users should instead follow the standard screening schedule appropriate for their age, health history, family history, smoking history, and other risk factors.
That may include recommended screening for colorectal, breast, cervical, lung, prostate, or other cancers, depending on the individual. A clinician can help determine which tests are appropriate and when they should begin.
Anyone experiencing persistent or unexplained symptoms should seek medical evaluation rather than waiting for a routine screening appointment. Concerning symptoms may include unexplained weight loss, blood in the stool, an ongoing cough, unusual bleeding, a new lump, persistent abdominal pain, or a major change in bowel habits. These symptoms can have many noncancerous causes, but they still deserve attention.
How should unused Belviq be discarded?
A medication take-back program is the preferred disposal method. A pharmacist, local waste authority, or law enforcement agency may provide information about nearby collection sites.
When take-back service is unavailable, FDA instructions allow the tablets to be mixedwithout crushingwith an undesirable substance such as used coffee grounds, dirt, or cat litter. The mixture should be sealed in a bag or container and placed in household trash. Personal information should be removed from the prescription label.
What About Other Weight Loss Medications?
The Belviq withdrawal does not mean that every prescription weight loss medication causes cancer or that medical weight management is inherently unsafe. Different drugs act through different biological pathways and carry different benefits, contraindications, side effects, and long-term safety data.
Obesity is a chronic, complex condition influenced by genetics, hormones, medications, sleep, mental health, food access, physical environment, and many other factors. Telling someone to “just eat less” is approximately as sophisticated as repairing a laptop by firmly telling it to behave.
Depending on a person’s health, a clinician may discuss structured nutrition therapy, physical activity, behavioral support, an FDA-approved anti-obesity medication, treatment of contributing medical conditions, or metabolic and bariatric surgery.
The most appropriate option depends on factors such as BMI, diabetes status, cardiovascular disease, kidney or liver function, pregnancy plans, medication interactions, eating disorder history, insurance coverage, side-effect tolerance, and personal preferences.
Never replace Belviq with an unapproved product
Former users should be cautious about supplements or online products claiming to contain lorcaserin or to provide “the same results as Belviq.” The FDA has discovered undeclared lorcaserin in certain illegally marketed weight loss products after the prescription drug was withdrawn.
Hidden pharmaceutical ingredients are particularly risky because consumers cannot confirm the dosage, purity, interactions, or manufacturing quality. A bottle decorated with leaves and the word “natural” is not automatically a tiny forest-based medical school.
What the Belviq Withdrawal Teaches About Drug Safety
FDA approval is not the end of safety monitoring
Clinical trials conducted before approval involve a limited number of participants and may last only months or a few years. Rare adverse effects can remain invisible until a medication is used by larger populations or studied for longer periods.
Postmarketing research, adverse-event reports, insurance databases, medical records, laboratory studies, and required safety trials all help regulators detect problems that were not obvious during the original approval process.
A trial can answer a question nobody expected to ask
CAMELLIA–TIMI 61 was designed mainly to evaluate cardiovascular safety. It succeeded in answering that question, but the cancer data ultimately had a greater effect on the medication’s future.
That is how science is supposed to work. Researchers begin with a planned question, examine the full results, and follow important signals instead of stuffing inconvenient numbers into the statistical junk drawer.
Benefits matter as much as risks
Almost every effective medication carries some risk. The relevant question is not whether a drug is perfectly safe, because perfectly safe medicines occupy the same shelf as unicorn vitamins. The question is whether the expected benefit is large enough to justify known and potential harms for a particular patient.
A small safety concern might be acceptable for a lifesaving cancer therapy with no equivalent alternative. The same concern may be unacceptable for a medication that provides modest average weight loss and can be replaced with other strategies.
Experiences After Belviq Was Removed From Shelves
The withdrawal was not merely a regulatory event involving percentages, reports, and sternly formatted government announcements. For patients who had built daily routines around Belviq, it created practical and emotional challenges. The following experience-based situations reflect common concerns that can arise when a long-term medication is unexpectedly removed. They are not presented as quotations from specific individuals.
Experience 1: The sudden pharmacy surprise
Some patients first learned about the withdrawal while attempting to refill a prescription. They may have arrived at the pharmacy expecting an ordinary transaction and instead heard that the medication was no longer available.
That kind of surprise can be unsettling, especially when the medicine seemed to be working. A patient may wonder whether stopping immediately is dangerous, whether another pharmacy still has stock, or whether a few remaining tablets should be stretched until the next medical appointment.
In this situation, the correct response was not to hunt for leftover inventory. The FDA advised patients to stop lorcaserin and contact the prescribing professional. Pharmacists also played an important role by explaining the withdrawal, preventing further dispensing, and helping patients understand safe disposal.
Experience 2: Anxiety about past exposure
Cancer-related headlines naturally produced fear among former users. Someone who had taken Belviq for several years could easily interpret “increased occurrence of cancer” as a personal diagnosis waiting to happen.
Understanding the absolute numbers helped place the concern in context. The difference between the lorcaserin and placebo groups was 0.6 percentage points, and the study did not establish that every additional cancer was caused by the medication.
Many former users benefited from discussing their individual cancer risk with a clinician instead of repeatedly searching alarming headlines at 2 a.m. The most useful conversation covered treatment duration, personal and family history, smoking history, existing symptoms, and whether routine screening was current.
For most people, the recommended plan was ordinary evidence-based screeningnot a full-body scan, a suitcase of blood tests, or a weekly appointment with Dr. Internet.
Experience 3: Fear of regaining weight
A patient who had lost weight while taking Belviq might have worried that appetite would return after the medication was stopped. That concern was reasonable. Weight regulation is biological, and stopping a medicine that suppresses appetite can make hunger or food cravings more noticeable.
The most constructive transition involved creating a replacement plan rather than treating the withdrawal as a test of willpower. A clinician could review previous results, identify medical conditions affected by weight, and discuss other evidence-based treatments.
Some patients might benefit from another approved medication, while others may prefer structured nutrition counseling, behavioral therapy, supervised physical activity, sleep treatment, or evaluation for bariatric surgery. A replacement plan does not need to look exactly like the old plan to be successful.
Experience 4: Frustration with the approval system
Former patients sometimes felt betrayed when they learned that an FDA-approved drug had later been withdrawn. “How was this approved in the first place?” is a fair question.
Approval means that available evidence supports a favorable benefit-risk balance for the intended population at that time. It does not guarantee that every rare or long-term complication is already known. Detecting a small increase in cancer may require thousands of participants and years of follow-up.
In the case of Belviq, the required postmarketing trial was precisely what uncovered the concerning signal. The withdrawal therefore demonstrated both a limitation and a strength of the system: preapproval research cannot reveal everything, but continued monitoring can change medical decisions when new evidence appears.
Experience 5: A more careful approach to future treatments
The experience encouraged many patients to ask better questions before beginning another weight management medication. How much weight do people typically lose? What side effects are common? What serious warnings exist? How long has the drug been studied? What happens if treatment stops? Which symptoms should prompt a call?
Those questions do not signal distrust. They are part of informed consent and shared decision-making. Patients should understand both the likely benefit and the uncertainty surrounding any long-term therapy.
Belviq also illustrated why follow-up appointments matter. A prescription should not disappear into a medical black hole after it is written. Regular monitoring allows patients and clinicians to assess effectiveness, side effects, laboratory results, changing health conditions, and newly released safety information.
Conclusion
Belviq and Belviq XR were removed from the U.S. market after a large required safety trial found a small but concerning increase in cancer diagnoses among people taking lorcaserin. The trial reported cancer in 7.7% of lorcaserin users and 7.1% of placebo recipients, with pancreatic, colorectal, and lung cancers contributing to the imbalance.
Researchers did not prove that lorcaserin directly caused the cancers. However, because the drug’s average weight loss benefit was moderate and the imbalance increased with longer exposure, the FDA concluded that its potential risks outweighed its benefits.
Former users are not advised to undergo special cancer screening solely because they took Belviq. They should follow standard screening recommendations, discuss individual concerns or symptoms with a licensed medical professional, and avoid old tablets or unapproved products containing lorcaserin.
Most importantly, the withdrawal should not discourage people from seeking evidence-based obesity treatment. It should encourage thoughtful treatment selection, realistic expectations, regular follow-up, and respect for the unglamorous but essential work of long-term drug safety monitoring.
